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ABSTRACT
We report here a chemical study on a Re analogue of one of the few cationic Tc-99m tracers
previously investigated as an agent for effective renal plasma flow (ERPF) measurement. Cationic Tc-99m
tracers have the potential for overcoming problems associated with common anionic Tc-99m tracers in
patients who have developed a uremic state. The Tc-99m-DACH tracer, prepared from 1,2-
diaminocyclohexane (I,2-DACH), is the only cationic renal agent tested in humans and has seven possible
isomers. The complex isolated from the reaction of the racemic mixture, (+)-trans-l,2-DACH, and
RelOz(PPh3)z after conversion to the BPh4 salt was found by X-ray crystallography to be the meso isomer,
trans-[ReO(trans-R,R-l,2-DACH)(trans-S,S-l,2-DACH)][BPh4]oMeOHo2HzO (1). The structural
parameters for 1 are normal. The complex is highly symmetrical, suggesting that the analogous meso Tc-
99m-DACH agent is also symmetrical. Studies of other Tc-99m-DACH agents that were made from cis-1,2-
DACH or individual trans-1,2-DACH enantiomers show that the biodistribution is not very dependent on the
starting 1,2-DACH ligand stereochemistry; these agents must be less symmetrical than the meso Tc-99m-
DACH agent analogue of 1. Thus, the overall charge and lipophilicity (similar for all Tc-99m-DACH
isomers) exert a greater influence on biodistribution than the specific structural features of the different Tc-
99m-DACH isomers.
INTRODUCTION
A simple and accurate measurement of effective renal plasma flow (ERPF) could lead to improved
diagnosis and management of patients with pre-renal azotemia and for the development of better strategies
for prevention and reversal of renal failure. With the development of the uremic state, there is a progressive
buildup of organic anions in plasma,
t These accumulated anions can competitively inhibit renal tubular
transport, reduce the clearance of anionic substrates, and lead to variable or spuriously low measurements of
ERPF and tubular function, t’ 5. -8 Most studies directed at finding a superior renal agent have focused on
anionic Te-99m agents,’, ’ but these must have an extraordinarily high affinity for the tubular transport
receptor to avoid the problem of competitive inhibition by organic anions in plasma. Evidence exists that this
problem can be avoided, however, by the development of a cationic tracer for ERPF measurement. C-14
tetraethylammonium cation (TEA), one of the earliest cationic agents investigated is secreted by the renal
tubular organic base transport mechanism.
t Studies in azotemic dogs demonstrated that the extraction
fraction ofTEA was significantly higher than that of the "gold standard" para-aminohippurate (PAH) anion;
in addition, unlike PAH, the extraction ofTEA was independent of the level of blood urea nitrogen? On the
basis of these studies, the investigators concluded that TEA is superior to PAH for the evaluation of the renal
circulation in azotemia. The most useful radioisotope for radiopharmaeeuticals is 99mTc.
For these reasons, we have initiated our research program aimed at finding clinically useful cationic
renal agents with a chemical study ofTe-99m-DACH, the only Tc-99m cationic renal agent for which studies
in humans have been reported,
t Tc-99m-DACH, the product of labeling 1,2-diaminocyclohexane (1,2-
DACH),t’" is non-toxic, only 20% protein bound, and is cleared more rapidly than tracers measuring the
glomerular filtration rate (GFR); therefore, transport of Tc-99m-DACH into the urine must be through the
tubules. The clearance of Tc-99m DACH can be competitively blocked using thiamine as a cationic
competitor, confirming cationic tubular transport; infusion of thiamine has no effect on tracers used to
measure glomerular filtration or on the tubular transport of anionic tracers,t’ ts The clearance of Tc-99m-
DACH is 80% of that ofOIH in the mouse but only 30% of that ofOIH in healthy human volunteers, t’’ ’" The
chemical form of the Tc-99m-DACH agent studied by Solanki and others is not well characterized and may
contain a single or a mixture of isomeric forms. The 1,2-DACH ligand has three isomers: one cis isomer
(with R and S carbons and thus the meso form) and two trans isomers (normally available as a racemic
mixture of R,R and S,S enantiomers). The Tc-99m-DACH agent likely contains two 1,2-DACH ligands and
can be formulated as trans-[TcOz(l,2-DACH)]+. Thus, seven different Tc-99m-DACH isomers are possible
with a trans TcO2
+ core (Figure 1). Different isomeric forms of anionic renal tracers may have widely
different clearances,
t’, 7 and, by analogy, different isomeric forms of cationic renal tracers may also have very
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different clearances. In fact, one of the Tc-99m-DACH isomers could have a high clearance in humans but
that clearance could be obscured by the relatively low clearances of the other isomers in a mixture. To test
this possibility, we previously compared renal excretion and biodistribution in Sprague-Dawley rats of Tc-
99m-cis-1,2-DACH, Tc-99m-trans-R,R-1,2-DACH, Tc-99m-trans-S,S-DACH and a Tc-99m-trans-(+)- 1,2-
DACH isomeric mixture,
is This mixture was found by HPLC to contain the statistically expected mixture of
25% Tc-99m-trans-S,S-1,2-DACH, 25% Tc-99m-trans-R,R-1,2-DACH, and 50% meso-Tc-99m-(trans-R,R-
/S,S-1,2-DACH). Little difference was found, however, in the rate of renal excretion or biodistribution of the
isomers.
trans-[MO2(trans-R,R-1,2-DACH)2]+ trans-[MO2(trans-S,S-1,2-DACH)2]+
,H I[I,H !-I1[I H,, "1+
H
0 H.I
trans-[MO2(trans-R,R-1,2-DACH)(trans-S,S-1,2-DACH)]+ trans-[MO2(cis-l,2-DAcH)2]
+
meso isomer
Figure 1. Schematic drawing of some possible isomers of trans-[MOz(1,2-DACH)2]
+ cations; isomers in
which cis- and trans-l,2-DACH are within the same complex are not shown. One possible isomer of the
complex with the cis-I,2-DACH ligand has both cyclohexane rings pointing in the same direction (shown);
the other isomer, with rings pointing away from each other to either side of the coordination plane, is not
shown.
An important aspect of Tc-99m radiopharmaceutical development is the study of the Re analogues,
which typically have nearly identical structures to the Tc counterpart and which are environmentally more
desirable compounds for chemical study. In this study, we determined the crystal structure of a Re analogue
of one trans-[TcOz(I,2-DACH)2]X isomer so that we could begin to identify the specific structural features
associated with rapid cationic renal transport.
MATERIALS AND METHODS
RelO2(PPh3)2 was prepared according to the literature procedure.
’9 The racemic mixture of ligands,
(+)-trans-1,2-diaminocyclohexane ((+)-trans-1,2-DACH) was obtained from Aldrich. Elemental analyses
were performed by Atlantic Microlabs, Atlanta, GA. The IR spectrum (KBr pellet) was recorded on a Nieolet
510M instrument.
Synthesis. trans-[ReO2(trans-l,2-DACH)2ll.H20. ReO2I(PPh3)2 (0.43 g, 0.5 mmol) was suspended
in MeOH (5 mL); (+)-trans-l,2-DACH (0.23 g, 2.0 mmol) was added, and the reaction mixture was heated
at reflux for 30 min. After the solution was cooled to room temperature, the pale yellow precipitate that
formed was collected, washed with chilled MeOH, and air dried. Yield, 0.13 g (45%). An analytical sample
was prepared by recrystallization from MeOH. Anal. Calcd for the monohydrate CI2H30IN403Re: C, 24.37;
H, 5.11; N, 9.47. Found: C, 24.52; H, 5.10; N, 9.20.
trans-[ReO2(trans-l,2-DACHhl[BPh4l.MeOH.2HzO (1). The iodide salt (0.11 g, 0.2 mmol) and Na[BPh4]
(0.07 g, 0.2 mmol) were dissolved in MeOH (10 mL). Yellow crystals of trans-[ReO2(trans-l,2-
diaminocyclohexane)2][BPh4].MeOH.2H20, deposited after addition of H20 to a faint cloudiness, were
collected and air dried. X-ray quality crystals were obtained from the filtrate following collection of the first
crop of microcrystals. Yield, 98 mg (59%). Anal. Calcd for the monohydrate C37H56BN405.Re." C, 53.29; H,
6.77; N, 6.72. Found: C, 53.87; H, 6.72; N, 6.79. FTIR: Spectrum in the 550 to 1200 em" range of I was
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nearly identical to that of Na[BPh4], except for a strong band at 808 cm", which is assigned tOVRe--O. The 1H
NMR spectra of all trans-[ReO2(1,2-DACH)2][BPh4] isomers examined in DMSO-d6 are relatively
uninformative, containing broad peaks for the 1,2-DACH ligand in the range ~1-2 ppm and for the [BPh4]"
counterion in the range 6.7-7.4 ppm.
X-ray Crystallography. An orange crystal of I of approximate dimensions 0.28 x 0.22 x 0.22 mm
was mounted under Paratone-8277 onto a glass fiber, and immediately placed in a cold nitrogen stream at
-80 C on the X-ray diffractometer. X-ray intensity data were collected on a standard Siemens SMART
CCD Area Detector System equipped with a normal focus molybdenum-target X-ray tube operated at 2.0 kW
(50 kV, 40 mA). Data (1321 frames, 1.3 hemispheres) were collected using a narrow frame method with
scan widths of 0.3* in o and exposure times of 10 s/flame using a detector-to-crystal distance of 5.09 cm
(maximum 20 angle of 56.6). The total data collection time was approximately 6 h. Frames were integrated
to a maximum 20 angle of 56.3 with the Siemens SAINT program to yield a total of 21389 reflections, of
which 8364 were independent (Rint 1.77%, Rsig 2.34%) and 7117 were above 2o(I). Laue symmetry
revealed a monoclinic crystal system, and the final unit cell parameters were determined from the least-
squares refinement of three-dimensional eentroids of 8192 reflections. Data were corrected for absorption
with the SADABS program,s
The space group was assigned as 12/a and the structure was solved by using direct methods and
refined employing full-matrix least-squares ’F on (Siemens SHELXTL, version 5.04). The structures refined
to a goodness of fit of 1.009 and final residuals ofR 3.30% [I>2o(I)], wRy_ 8.42% [I>2o(I)].
RESULTS AND DISCUSSION
99mTc radiopharmaceuticals are characterized chemically by preparing 99Tc and Re derivatives. 99Tc
derivatives provide the most representative chemical data for 99raTe radiopharmaceuticals. However, since
the half-life of 99Tc is ~200,000 years, the isotope poses a serious contamination hazard. 99Tc and Re
complexes have essentially identical physical properties and hence identical structures. Naturally occurring
Re is non-radioactive and environmentally preferable. Since our aim was to understand the structure of Tc-
99m-DACH isomers, we prepared a Re derivative. Ligand exchange of RelO2(PPh3)z with (+)-trans-l,2-
DACH proceeded cleanly with an excess (4 equiv) of diamine. Conversion of the I" salt to the [BPh4] salt
aided crystallization ofthe trans-[ReOz(trans-1,2-DACH)z]
+ cation for the X-ray diffraction study.
C3
C2
C1
N1
Re1
C5 N2
01
Figure 2. Perspective drawing of cation #1 of trans-[ReO2(trans-R,R-l,2-DACH)(trans-S,S-1,2-
DACH)][BPh4]oMeOHo2H20 (1) with 50% probability for the thermal ellipsoids.
X-ray Crystallography. The single crystal selected for the X-ray diffraction study consisted of the meso
isomer (1) with one trans-R,R- and one trans-S,S-1,2-DACH ligand. Crystal data and refinement parameters
are presented in Table 1. The asymmetric unit of I consists of two independent cations. For each cation the
metal atom is located at a special position (inversion center, occupancy one hal0; the second half of each
cation is generated by the symmetry operations -x+3/2,-y+l/2,-z+l/2 (cation #1) and-x,-y,-z (cation #2).
Differences in bond distances and angles within the inner coordination sphere of the two cations were
insignificant (Table 2). Figure 2 shows a perspective drawing of cation #1. Selected bond distances and
angles for both cations are listed in Table 2.
The cation of I is a trans-dioxo complex with two 1,2-DACH ligands coordinated in the equatorial
plane. The Re-N and Re-O bond distances are normal?’ Bond angles within the inner coordination sphere
correspond to a regular octahedron within o, except that the bite angles of the DACH ligands are acute
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(79), while the inter-ligand N-Re-N bond angles are obtuse (101). The 1,2-DACH ligands adopt a chair
conformation. In cation #1, the conformation of the 1,2-DACH ligands is flattened, with torsion angles
ranging from 21-26, compared to the 56 values obtained for cyclohexane in the gas phase? For cation #2,
the torsion angles within the cyclohexane ring were larger (38-51) but still smaller than observed for the
uncoordinated ligand.
Table 1. Crystal Data for trans-[ReO2(trans-R,R-l,2-DACH)(trans-S,S-1,2-DACH)][BPh4].MeOHo2H20 (1)
chemical formula C37H52BN4OsRe
fw 829.84
T(K) 193 (2) , (A) 0.71073
space group 12/a
unit cell dimensions a 18.77350 (10) A
b 20.7075 (3)A
c 19.1457 (3) A
fl 99.2170 (10) deg
V (A) 7346.8 (2)
Z 8
Pealed(gcm"3) 1.500
absorption coefficient 3.354 mm
"l
R indices [I> 2t(/)] R 0.0330, wRy. 0.0842
R indices (all data) R 0.0409, wR2 0.0884
Deposition number CCDC 145438
2 I/2 "R ([[Fo[- .d)/ZlFo[ and wR2 [Z[w(Fo Fc ]/Zw(Fo )]]
where w t/[oFo- + (aP) + bP] ande [(max;0,Fo’) + 2Fc’]/3
Table 2. Selected Bond Distances (A) and Angles (deg) for trans-[ReO2(trans-R,R-l,2-DACH)(trans-S,S-
1,2-DACH)][BPh4]MeOH.2H20 (1). Atoms generated by symmetry operations are indicated by #1 for
cation # 1, and #2 for cation #2f
Bond Distances (A)
Re(1)-O(l) 1.760(3) Re(2)-O(2) 1.765(3)
Re(1)-N(l) 2.165(3) Re(2)-N(3) 2.158(4)
Re(1)-N(2) 2.165(3) Re(2)-N(4) 2.175(3)
Bond Angles (deg)
O(1)-Re(1)-O(1)#1 180 O(2)#2-Re(2)-O(2) 180
O(1)-Re(1)-N(1)#1 89.57(14) O(2)-Re(2)-N(3) 89.3(2)
O(1)-Re(l)-N(1) 90.43(14) O(2)-Re(2)-N(3)#2 90.7(2)
N(1)#1-Re(1)-N(1) 180 N(3)-Re(E)-N(3)#2 180
O( )# -Re( )-N(2) 89.0(2) O(2)#2-Re(2)-N(4) 90.59(14)
O(1)-Re(1)-N(2) 91.0(2) O(2)-Re(E)-N(4) 89.41(14)
N( )#1-Re( )-N(2) 10 I. 10(13) N(3)-Re(E)-N(4)#2 01.2(2)
N(I)-Re(1)-N(2) 78.90(13) N(3)-Re(2)-N(4) 78.8(2)
aSymmetry transformations used to generate equivalent atoms: #I -x+3/2,-y+l/2,-z+ 1/2; #2 -x,-y,-z
The renal clearance of anionic Te-99m agents is in general promoted by the presence of an ionized
carboxylate group attached to an organic chelating ligand?
2 The carboxyl group most likely interacts with
the transport receptor. Normally, such anionic Te-99m agents contain a Tc(V)O core, the oxo ligand of
which may also interact with the transport receptor. However, the metal itself is not involved in receptor
recognition. In the case of cationic Tc-99m agents, the center of residual positive charge is associated with
the metal buried within the trans ToO2 core. The metal itself does not directly influence distribution but the
oxo ligands, being trans to each other, directly compete to donate electrons into the metal d orbitals.
Therefore, the oxo ligands will have more residual charge than the one oxo ligand in the typical renal agent.
At present, it is unclear how the axial oxo ligand and also the equatorial ligands affect renal uptake in
cationic Tc-99m agents. Our belief that a data base of structural information should help resolve this
uncertainty prompted this study.
The structure of the trans-[ReO2(trans-R,R-1,2-DACH)(trans-S,S-l,2-DACH)]
/ cation as determined
here by X-ray methods provides some useful starting data. The complex is highly symmetrical; consequently
only half of the molecule is unique. The molecule has a symmetrical distribution of charge, but on the basis
of this structure it is clear that other Tc-99m-DACH isomers must have an unsymmetrical distribution. Thus,
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overall charge and lipophilicity (similar for all Tc-99m-DACH isomers) exert a greater influence on
biodistribution than do the specific structural features of the different Tc-99m-DACH isomers. At present,
structural and renal clearance data are limited to relatively few cationic species; 3’ 12.5, 2,, 7 additional studies
combining biodistribution and renal clearance experiments of cationic Tc-99m agents with structure
determinations of the Re analogues are needed to establish the structure-distribution relationships required
for the development ofa clinically useful cationic Tc-99m renal agent.
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